Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 323

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 323
---
 to treatment;                              |

| ● | Ease of use of DiamiR’s tests: they are minimally invasive, 
 based on analysis of plasma;                                |

| ● | Potential cost advantage of DiamiR’s tests compared        
 to imaging and analysis of cerebrospinal fluid biomarkers; |

| ● | DiamiR’s collaborations with high profile academic clinical 
 centers; and                                                |

| ● | Value to customers (e.g. asymptomatic subjects in high-risk 
 groups) promoting repeat testing (e.g. annual screening).   |

DiamiR believes that its success will
depend on its ability to expeditiously:

| ● | Launch the tests in the US and expand in countries outside 
 of the US;                                                 |

| ● | Continue to innovate and maintain scientifically advanced 
 technology;                                               |

| ● | Market and sell DiamiR’s tests, initially as a clinical    
 research tool for pre-selection of patients for AD trials; |

| ● | Expand DiamiR’s tests to provide information on other 
 NDs;                                                  |

| ● | Optimize DiamiR’s sample collection process; |

| ● | Publish clinical studies in peer-reviewed journals; |

| ● | Continue to validate DiamiR’s tests, especially with 
 respect to treatment benefit;                        |

| ● | Attract and retain skilled personnel; |

| ● | Protect DiamiR’s products and technology with patents; |

| ● | Assure the quality of DiamiR’s LDTs produced under FDA 
 and CLIA guidelines;                                   |

| ● | Assure that the CLIA lab where tests are produced continue 
 to maintain all appropriate licenses; and                  |

| ● | Meet necessary regulatory requirements. |

<div align='center'>186</div>

Payment and reimbursement

The principal groups that DiamiR expects
to pay for its molecular testing services include:

| ● | Biopharmaceutical companies conducting clinical trials; |

| ● | Clinical centers, including memory, brain health and geriatric            
 centers that will pay negotiated rates for their clinicians’ test orders; |

| ● | Commercial third-party payors, based on existing or novel 
 Current Procedural Terminology (CPT) and/or PLA codes;    |

| ● | Government and private payors, with whom DiamiR plans to initiate     
 a dialog and to submit relevant applications as soon as feasible; and |

| ● | Patients and at-risk individuals who pay co-payments, deductibles              
 and other amounts that DiamiR is unable to